For the first time, the U.S. Food and Drug Administration (FDA) has approved the use of a ketamine-like drug as a stand-alone therapy for adults with treatment-resistant depression (TRD).

To address esketamine's side effects, the FDA will require that the drug be given in the presence of a clinician so patients can be monitored for a few hours. "Because of [safety] concerns ...

The FDA has approved Janssen’s antidepressant ... who have cycled through multiple treatments without relief. Spravato (esketamine) has been touted as a potential blockbuster for Janssen ...

Alert FDA OKs Mesenchymal Stromal Cell Therapy for GVHD Remestemcel-L (Ryoncil) is an allogeneic bone marrow‒derived mesenchymal stromal cell therapy for steroid-refractory acute graft-vs-host ...

This is because the Food and Drug Administration (FDA) only approves the drug ketamine for use in general anesthetics. However, Medicare may cover the drug Spravato, which contains esketamine.

In terms of the newest collaboration, the health care professionals said they decided that having all the services under one ...

There is hope for your symptoms. The clinic also offer the FDA approved Spravato (Esketamine) for treatment resistant depression, anxiety, and PTSD. Call for inquiries. Immediate appointment times ...